BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29215848)

  • 1. Molecular biology of brain meningiomas.
    Byvalsev VA; Stepanov IA; Belykh EG; Yarullina AI
    Patol Fiziol Eksp Ter; 2017; 61(2):82-91. PubMed ID: 29215848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Targets and Treatment of Meningioma.
    Miller R; DeCandio ML; Dixon-Mah Y; Giglio P; Vandergrift WA; Banik NL; Patel SJ; Varma AK; Das A
    J Neurol Neurosurg; 2014; 1(1):. PubMed ID: 25485306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.
    Choy W; Kim W; Nagasawa D; Stramotas S; Yew A; Gopen Q; Parsa AT; Yang I
    Neurosurg Focus; 2011 May; 30(5):E6. PubMed ID: 21529177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetics of meningiomas.
    Ragel BT; Jensen RL
    Neurosurg Focus; 2005 Nov; 19(5):E9. PubMed ID: 16398473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biological and diagnostic roles of MicroRNAs in meningiomas.
    Wang L; Chen S; Liu Y; Zhang H; Ren N; Ma R; He Z
    Rev Neurosci; 2020 Oct; 31(7):771-778. PubMed ID: 32697762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetics of meningiomas: from basic research to potential clinical applications.
    Simon M; Boström JP; Hartmann C
    Neurosurgery; 2007 May; 60(5):787-98; discussion 787-98. PubMed ID: 17460514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetic strategy to overcome the senescence of primary meningioma cell cultures.
    Baia GS; Slocum AL; Hyer JD; Misra A; Sehati N; VandenBerg SR; Feuerstein BG; Deen DF; McDermott MW; Lal A
    J Neurooncol; 2006 Jun; 78(2):113-21. PubMed ID: 16554968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningioma: an update.
    Lusis E; Gutmann DH
    Curr Opin Neurol; 2004 Dec; 17(6):687-92. PubMed ID: 15542977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
    Bie L; Zhao G; Ju Y; Zhang B
    Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of epigenetic and gene expression alterations associated with intracranial meningiomas.
    He S; Pham MH; Pease M; Zada G; Giannotta SL; Wang K; Mack WJ
    Neurosurg Focus; 2013 Dec; 35(6):E5. PubMed ID: 24289130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic landscape of meningioma.
    Yuzawa S; Nishihara H; Tanaka S
    Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningioma: Signaling pathways and tumor growth.
    Burnett BA; Womeldorff MR; Jensen R
    Handb Clin Neurol; 2020; 169():137-150. PubMed ID: 32553285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
    Nassehi D
    Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation markers of malignant potential in meningiomas.
    Vengoechea J; Sloan AE; Chen Y; Guan X; Ostrom QT; Kerstetter A; Capella D; Cohen ML; Wolinsky Y; Devine K; Selman W; Barnett GH; Warnick RE; McPherson C; Chiocca EA; Elder JB; Barnholtz-Sloan JS
    J Neurosurg; 2013 Oct; 119(4):899-906. PubMed ID: 23930849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of epithelial membrane protein 2 (EMP2) as a molecular marker and correlate for angiogenesis in meningioma.
    Patel KS; Kejriwal S; Sun MM; Thammachantha S; Duong C; Chan A; Cherian N; Romiyo P; Gordon LK; Yong W; Wadehra M; Yang I
    J Neurooncol; 2020 Mar; 147(1):15-24. PubMed ID: 31981014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.
    Kliese N; Gobrecht P; Pachow D; Andrae N; Wilisch-Neumann A; Kirches E; Riek-Burchardt M; Angenstein F; Reifenberger G; Riemenschneider MJ; Meese E; Panayotova-Dimitrova D; Gutmann DH; Mawrin C
    Oncogene; 2013 Sep; 32(39):4712-20. PubMed ID: 23108408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.
    Ludwig N; Kim YJ; Mueller SC; Backes C; Werner TV; Galata V; Sartorius E; Bohle RM; Keller A; Meese E
    Neuro Oncol; 2015 Sep; 17(9):1250-60. PubMed ID: 25681310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the role of epidermal growth factor receptor variant III in meningeal tumors.
    Rana R; Rathi V; Chauhan K; Jain K; Chhabra SS; Acharya R; Kalra SK; Gupta A; Jain S; Ganguly NK; Yadav DK
    PLoS One; 2021; 16(9):e0255133. PubMed ID: 34582442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathogenesis of meningiomas.
    Perry A; Gutmann DH; Reifenberger G
    J Neurooncol; 2004 Nov; 70(2):183-202. PubMed ID: 15674477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
    Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
    Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.